Show simple item record

dc.contributor.authorReikvam, Håkonen_US
dc.contributor.authorSkavland, Jørnen_US
dc.contributor.authorGullaksen, Stein-Eriken_US
dc.contributor.authorHovland, Randien_US
dc.contributor.authorGedde-Dahl, Tobiasen_US
dc.contributor.authorBruserud, Øysteinen_US
dc.contributor.authorGjertsen, Bjørn Toreen_US
dc.PublishedReikvam H, Skavland J, Gullaksen S, Hovland R, Gedde-Dahl T, Bruserud Ø, Gjertsen BT. Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. Case reports in hematology. 2018;2045985eng
dc.description.abstractChronic myeloid leukemia (CML) is a myeloproliferative disorder in which neoplastic cells exhibit the Philadelphia chromosome and the related oncoprotein BCR-ABL1. Allogeneic stem cell transplantation (allo-SCT) was considered the first-line treatment for CML, before the introduction of tyrosine kinase inhibitors (TKIs). However, patients are at risk for relapse years after transplantation. We present a patient who relapsed 25 years after allo-SCT for chronic phase CML. Polymerase chain reaction (PCR) detected gradually evaluated levels of BCR-ABL1 transcripts, eventually leading to the diagnosis of relapsed disease. Additional mutational analyses did not reveal mutations in the BCR-ABL1 gene, or other cooperating mutations. The patient was successfully treated with imatinib 400 mg daily, leading to new molecular remission. The case presentation emphasizes the need for long-term follow-up of such patients and the potential benefit of initiating TKI treatment with early signs of relapse.en_US
dc.rightsAttribution CC BYeng
dc.titleChronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantationen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2018 The Authors
dc.source.journalCase reports in hematology

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY